CA3079156A1 - Novel gamma delta t-cell receptor and its ligand - Google Patents

Novel gamma delta t-cell receptor and its ligand Download PDF

Info

Publication number
CA3079156A1
CA3079156A1 CA3079156A CA3079156A CA3079156A1 CA 3079156 A1 CA3079156 A1 CA 3079156A1 CA 3079156 A CA3079156 A CA 3079156A CA 3079156 A CA3079156 A CA 3079156A CA 3079156 A1 CA3079156 A1 CA 3079156A1
Authority
CA
Canada
Prior art keywords
tcr
cell
clone
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079156A
Other languages
English (en)
French (fr)
Inventor
Andrew Sewell
Garry DOLTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CA3079156A1 publication Critical patent/CA3079156A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
CA3079156A 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand Pending CA3079156A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1719169.3 2017-11-20
GBGB1719169.3A GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand
PCT/GB2018/053321 WO2019097244A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand

Publications (1)

Publication Number Publication Date
CA3079156A1 true CA3079156A1 (en) 2019-05-23

Family

ID=60805814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079156A Pending CA3079156A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand

Country Status (15)

Country Link
US (1) US11850264B2 (https=)
EP (1) EP3713954A1 (https=)
JP (1) JP2021505190A (https=)
KR (1) KR20200085776A (https=)
CN (1) CN111372944A (https=)
AU (1) AU2018369698A1 (https=)
BR (1) BR112020007469A2 (https=)
CA (1) CA3079156A1 (https=)
EA (1) EA202091276A1 (https=)
GB (1) GB201719169D0 (https=)
IL (1) IL274482A (https=)
MX (1) MX2020005200A (https=)
SG (1) SG11202002993UA (https=)
WO (1) WO2019097244A1 (https=)
ZA (1) ZA202002417B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230226183A1 (en) * 2020-01-15 2023-07-20 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
EP4059955A1 (en) 2021-03-19 2022-09-21 Medizinische Hochschule Hannover Hla-dr-specific gamma delta tcr constructs and use thereof
EP4472742A1 (en) 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
US20240043496A1 (en) * 2022-07-26 2024-02-08 Gadeta B.V. Delta t-cell or gamma receptor chains or parts thereof for treating ovarian cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
WO1996013593A2 (en) * 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
AU2002308481A1 (en) * 2001-05-01 2002-11-11 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
AU2002359666A1 (en) * 2001-12-10 2003-06-23 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
CN1842709A (zh) * 2003-07-10 2006-10-04 塞诺米克斯公司 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
PL3119807T3 (pl) * 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek

Also Published As

Publication number Publication date
ZA202002417B (en) 2021-07-28
US11850264B2 (en) 2023-12-26
US20200316124A1 (en) 2020-10-08
AU2018369698A1 (en) 2020-04-30
MX2020005200A (es) 2020-08-20
JP2021505190A (ja) 2021-02-18
SG11202002993UA (en) 2020-06-29
BR112020007469A2 (pt) 2020-11-03
EA202091276A1 (ru) 2020-09-04
WO2019097244A1 (en) 2019-05-23
IL274482A (en) 2020-06-30
EP3713954A1 (en) 2020-09-30
KR20200085776A (ko) 2020-07-15
CN111372944A (zh) 2020-07-03
GB201719169D0 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
JP7792114B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
KR102865130B1 (ko) 향상된 키메라 항원 수용체 및 그의 용도
US11078252B2 (en) T-cell receptor
KR102609624B1 (ko) 방법
US11850264B2 (en) Gamma delta T-cell receptor and its ligand
KR102238226B1 (ko) 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
CA3045338A1 (en) Production of engineered cells for adoptive cell therapy
US20190085081A1 (en) Chimeric antigen receptor
CN113840834B (zh) Magea1特异性t细胞受体及其用途
BR112021008973A2 (pt) Receptores de células t específicos para mesotelina e uso dos mesmos em imunoterapia
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
WO2019140278A1 (en) Immunotherapy targeting core binding factor antigens
US20210403528A1 (en) Novel T-Cell Receptor and Ligand
WO2023138661A1 (zh) Nkg2a抗体及其应用
TW202602928A (zh) 程序性死亡配體1(pd-l1)嵌合抗原受體及其應用
WO2024111635A1 (ja) 血液がんに対する抗体
EA045252B1 (ru) Новый т-клеточный рецептор

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241114

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250407

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260212